{"id":581328,"date":"2026-08-11T11:02:19","date_gmt":"2026-08-11T11:02:19","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/581328\/"},"modified":"2026-08-11T11:02:19","modified_gmt":"2026-08-11T11:02:19","slug":"abcellera-menopause-drug-cuts-hot-flashes-in-mid-stage-trial-shares-rise","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/581328\/","title":{"rendered":"AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise"},"content":{"rendered":"<p class=\"c-paragraph\">AbCellera said on Monday its experimental menopause treatment significantly reduced the frequency and severity of hot flashes in a mid-stage trial, sending its shares up nearly 40 per cent in early morning trading.<\/p>\n<p class=\"c-paragraph\">The drug, ABCL635, is being developed for women with moderate-to-severe vasomotor symptoms, commonly known as hot flashes, associated with menopause.<\/p>\n<p class=\"c-paragraph\">The data could bolster the drug\u2019s prospects as a non-hormonal alternative to hormone therapy and as a potential rival to currently available therapies, including Astellas Pharma\u2019s 4503.T oral treatment Veozah.<\/p>\n<p class=\"c-paragraph\">In the 92-patient study, a single 600-mg dose of ABCL635 significantly reduced the frequency and severity of moderate-to-severe hot flashes compared with placebo after four weeks.<\/p>\n<p class=\"c-paragraph\">Patients treated with ABCL635 reported an 83 per cent reduction in moderate-to-severe hot-flash frequency after four weeks, or 8.8 fewer hot flashes per day from baseline, compared with a 33 per cent reduction, or 3.5 fewer events per day, in the placebo group.<\/p>\n<p class=\"c-paragraph\">ABCL635 also improved symptom severity, sleep and patients\u2019 overall assessment of improvement.<\/p>\n<p class=\"c-paragraph\">BMO Capital Markets analyst Evan Seigerman said the positive trial results were \u201ctransformational\u201d for AbCellera, estimating a global market opportunity of about US$6 billion and forecasting potential peak annual sales of about $2.3 billion for ABCL635.<\/p>\n<p class=\"c-paragraph\">The most common side effects reported in patients treated with ABCL635 were headache, fatigue and injection-site reactions.<\/p>\n<p>Long-acting treatment<\/p>\n<p class=\"c-paragraph\">The non-hormonal antibody therapy is being developed as a long-acting, once-monthly injection that targets the neurokinin 3 receptor, which helps regulate body temperature.<\/p>\n<p class=\"c-paragraph\">Sarah Noonberg, AbCellera\u2019s chief medical officer, said the once-monthly injection could appeal to women already accustomed to self-injecting medicines, including breast cancer survivors and users of weight-loss drugs, and may improve adherence compared with daily pills.<\/p>\n<p class=\"c-paragraph\">Cantor analyst Steve Seedhouse said ABCL635 appeared more efficacious than even unapproved high doses of Astellas\u2019 Veozah, which were discontinued in development due to liver safety concerns.<\/p>\n<p class=\"c-paragraph\">AbCellera said additional 12-week data from the trial are expected later this year.<\/p>\n<p class=\"c-paragraph\">Reporting by Siddhi Mahatole in Bengaluru; Editing by Tasim Zahid.<\/p>\n","protected":false},"excerpt":{"rendered":"AbCellera said on Monday its experimental menopause treatment significantly reduced the frequency and severity of hot flashes in&hellip;\n","protected":false},"author":2,"featured_media":581329,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[6772,163,85,46,482],"class_list":["post-581328","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-apple-news","tag-health","tag-il","tag-israel","tag-medication"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/581328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=581328"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/581328\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/581329"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=581328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=581328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=581328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}